109 related articles for article (PubMed ID: 10821989)
1. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group.
Carrieri MP; Vlahov D; Dellamonica P; Gallais H; Lepeu G; Spire B; Obadia Y
Drug Alcohol Depend; 2000 Jul; 60(1):51-4. PubMed ID: 10821989
[TBL] [Abstract][Full Text] [Related]
2. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.
Moatti JP; Carrieri MP; Spire B; Gastaut JA; Cassuto JP; Moreau J
AIDS; 2000 Jan; 14(2):151-5. PubMed ID: 10708285
[TBL] [Abstract][Full Text] [Related]
3. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
4. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group.
Reynaud-Maurupt C; Carrieri MP; Gastaud JA; Pradier C; Obadia Y; Moatti JP
AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779
[TBL] [Abstract][Full Text] [Related]
5. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
[TBL] [Abstract][Full Text] [Related]
6. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
[TBL] [Abstract][Full Text] [Related]
7. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
[TBL] [Abstract][Full Text] [Related]
8. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
9. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.
Celentano DD; Galai N; Sethi AK; Shah NG; Strathdee SA; Vlahov D; Gallant JE
AIDS; 2001 Sep; 15(13):1707-15. PubMed ID: 11546947
[TBL] [Abstract][Full Text] [Related]
10. Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
Carrieri MP; Roux P; Cohen J; Ravaux I; Dellamonica P; Protopopescu C; Spire B; Rosenblum A
Addiction; 2010 Dec; 105(12):2160-8. PubMed ID: 20840169
[TBL] [Abstract][Full Text] [Related]
11. [Health related quality of life among HIV-HCV co-infected patients].
Préau M; Protopopescu C; Spire B; Dellamonica P; Poizot-Martin I; Villes V; Carrieri MP;
Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S33-1S43. PubMed ID: 17073128
[TBL] [Abstract][Full Text] [Related]
12. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.
Wolfe D; Carrieri MP; Shepard D
Lancet; 2010 Jul; 376(9738):355-66. PubMed ID: 20650513
[TBL] [Abstract][Full Text] [Related]
13. Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
Wood E; Hogg RS; Lima VD; Kerr T; Yip B; Marshall BD; Montaner JS
JAMA; 2008 Aug; 300(5):550-4. PubMed ID: 18677027
[TBL] [Abstract][Full Text] [Related]
14. Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs.
Pradier C; Carrieri P; Bentz L; Spire B; Dellamonica P; Moreau J; Moatti JP
Int J STD AIDS; 2001 May; 12(5):324-8. PubMed ID: 11368807
[TBL] [Abstract][Full Text] [Related]
15. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
Carrieri MP; Moatti JP; Vlahov D; Obadia Y; Reynaud-Maurupt C; Chesney M
J Epidemiol Community Health; 1999 Jan; 53(1):4-8. PubMed ID: 10326045
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
18. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
19. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users.
Bouhnik AD; Moatti JP; Vlahov D; Gallais H; Dellamonica P; Obadia Y;
J Epidemiol Community Health; 2002 May; 56(5):349-53. PubMed ID: 11964431
[TBL] [Abstract][Full Text] [Related]
20. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B; Lucas GM; Carrieri MP
Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
